AC Immune SA (NASDAQ: ACIU) has some early good news from its pipeline, even if the stock market didn't seem to care much. The company reported favorable interim results from a Phase 1 clinical trial for ACI-19764, an orally administered drug designed to target the NLRP3 inflammasome. That's a mouthful, but think of it as a key player in the body's inflammatory response, and one that's been linked to a bunch of nasty diseases.
AC Immune is a clinical-stage biopharmaceutical company that focuses on neurodegenerative conditions, so this is a bit of a different tack for them. The study, conducted in Europe, is looking at the drug's safety, tolerability, and how it moves through the body in healthy volunteers.
So far, so good. The early data show that ACI-19764 is safe and well-tolerated across single and multiple ascending dose groups. They tested doses up to 20mg daily, and the drug has a serum half-life of more than 30 hours. No serious adverse events, no one dropped out because of side effects. That's the kind of boring but essential news you want from a Phase 1 readout.
Getting Into the Brain and Doing Something
But it's not just about safety. The study also showed that the drug actually gets into the brain, which is kind of the whole point if you're targeting neurological diseases. They saw clear evidence of brain penetration through cerebrospinal fluid exposure. And at daily doses of 10mg or less, the drug reached concentrations above the IC90 threshold, which is a fancy way of saying it hit the level where it should be doing something.
Even better, a blinded review of whole blood assays confirmed that the drug successfully inhibited IL-1beta release in a dose-dependent manner. IL-1beta is a pro-inflammatory cytokine, so this is a direct signal that the drug is doing what it's designed to do: blocking the inflammatory cascade that drives disease progression across multiple metabolic, inflammatory, and neurological disorders.
What's Next for ACI-19764
Given these positive safety outcomes, the trial has already moved to a Phase 1b cohort. This time, they're dosing patients who are at risk for cardiovascular disease, specifically those with elevated high-sensitivity C-reactive protein (hsCRP) levels, along with obesity or type 2 diabetes. These are folks where chronic inflammation is a real problem, and the hope is that ACI-19764 can help tamp that down.
Patient recruitment is ongoing, and the company expects to release initial findings from this group before the end of the year. And with robust preclinical toxicity data in hand, the program is looking at additional clinical updates in the first half of 2027.
Martin Zügel, AC Immune's interim CEO, sounded pretty upbeat about the results. "These first-in-human data for ACI-19764 are encouraging, and represent not only an important milestone for this program, but also the wider clinical momentum of our wholly-owned programs…we are now poised to deliver key clinical evidence of anti-inflammatory activity (hsCRP inhibition) in the coming months." He added, "We believe ACI-19764 has the potential to be a powerful NLRP3 inhibitor, and we look forward to further exploring its therapeutic potential."
So, what does the market think? Not much, apparently. AC Immune shares were down 4.26% at $2.47 at the time of publication on Thursday. It's a reminder that early-stage data, even when positive, doesn't always move the needle. But for a company with a pipeline focused on neurodegenerative diseases, having a potential oral anti-inflammatory that gets into the brain is a nice card to have. We'll see if the Phase 1b data, due later this year, gives investors a reason to pay more attention.
